Huntleigh Advisors’s GeneDx Holdings WGS Stock Holding History

Huntleigh Advisors’s Portfolio WGS Stock Details WGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-17,996	Closed	-$2.34M	–	306
2025 Q4	$2.34M	Buy	17,996 +443	+3%	+$60.8K	0.4%	66
2025 Q3	$1.89M	Buy	17,553 +37	+0.2%	+$4.03K	0.32%	82
2025 Q2	$1.62M	Buy	17,516 +949	+6%	+$74.5K	0.31%	81
2025 Q1	$1.47M	Sell	16,567 -19,363	-54%	-$1.68M	0.25%	81
2024 Q4	$2.76M	Buy	+35,930	New	+$2.51M	0.59%	42

Other funds holding WGS

Corvex Management New York $3.27B AUM 38.53% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

ZDA

Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Huntleigh Advisors's WGS Position: Q1 2026 in Review

Huntleigh Advisors sold out of GeneDx Holdings (WGS) in Q1 2026, closing a stake of 17,996 shares — an estimated $2.34M sold.

Huntleigh Advisors first reported a position in WGS in Q4 2024 and held it in 5 quarters. The position peaked at $2.76M in Q4 2024. 240 funds tracked by Wall St. Rank hold WGS as of Q1 2026.

Huntleigh Advisors reported no remaining GeneDx Holdings position as of Q1 2026 after selling out during the quarter.
Huntleigh Advisors sold 17,996 GeneDx Holdings shares in Q1 2026, an estimated $2.34M.
Huntleigh Advisors first reported a position in GeneDx Holdings in Q4 2024 and held it in 5 quarters.
Huntleigh Advisors's GeneDx Holdings position peaked at $2.76M in Q4 2024.
240 funds tracked by Wall St. Rank held GeneDx Holdings as of Q1 2026.

Based on Huntleigh Advisors's 13F filing for Q1 2026, filed 21 Apr 2026.